Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration
- PMID: 3129541
Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration
Abstract
The pharmacokinetics of recombinant human interferon-gamma (rIFN-gamma) were studied in rhesus monkeys. Intravenous administration of 0.1 mg/kg yielded half-lives of 12.3-13.4 min and 130 min. Clearance after intravenous administration was 18.7 ml/min/kg, and the steady-state volume of distribution (Vdss) was 510 ml/kg. The peak serum concentrations after intramuscular and subcutaneous administration of 0.25 mg/kg rIFN-gamma were 50.7 and 52.3 ng/ml, respectively. The time to reach the peak serum concentration was 480 min for both routes. The mean bioavailabilities after intramuscular and subcutaneous administration were 109 and 90%, respectively. Intravenous administration of 0.25 mg/kg rIFN-gamma resulted in no significant change in the clearance, half-life, or Vdss, suggesting that the kinetics of rIFN-gamma are linear over the range of doses tested. Nearly all of the animals developed antibodies to rIFN-gamma after three doses. The presence of nonneutralizing antibodies to rIFN-gamma had no discernible effect on the calculated pharmacokinetic parameters.
Similar articles
-
Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep.Vet J. 2009 Jun;180(3):343-7. doi: 10.1016/j.tvjl.2007.11.025. Epub 2008 Apr 11. Vet J. 2009. PMID: 18406644 Clinical Trial.
-
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients.Cancer Res. 1985 Jun;45(6):2866-72. Cancer Res. 1985. PMID: 3921249
-
Pharmacokinetics and biodisposition of recombinant human interferon-alpha 2C in rat and marmoset.Arzneimittelforschung. 1988 Oct;38(10):1539-43. Arzneimittelforschung. 1988. PMID: 3196399
-
Interferon in the treatment of ovarian cancer.Semin Oncol. 1988 Oct;15(5 Suppl 5):26-9. Semin Oncol. 1988. PMID: 2461594 Review. No abstract available.
-
Clinical pharmacokinetics of interferons.Clin Pharmacokinet. 1990 Nov;19(5):390-9. doi: 10.2165/00003088-199019050-00003. Clin Pharmacokinet. 1990. PMID: 1702693 Review.
Cited by
-
Interferon gamma encapsulated into liposomes enhances the activity of monocytes and natural killer cells and has antiproliferative effects on tumor cells in vitro.Blut. 1990 Jul;61(1):30-7. doi: 10.1007/BF01739431. Blut. 1990. PMID: 2117474
-
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.Clin Pharmacokinet. 2005;44(4):331-47. doi: 10.2165/00003088-200544040-00001. Clin Pharmacokinet. 2005. PMID: 15828849 Review.
-
The role of pharmacokinetics in the development of biotechnologically derived agents.Clin Pharmacokinet. 1992 Dec;23(6):406-14. doi: 10.2165/00003088-199223060-00002. Clin Pharmacokinet. 1992. PMID: 1458760 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources